Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_759_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
47 Мб
Скачать
Rectus sheath
Strip of fascia trimmed
10 Segmental or Total Female Urethrectomy
Fig. 10.16 The autologous rectus sheath
113
about 5% of patients. Brubaker etal. reported a new onset of urinary urgency and urge inconti­nence in 1.2% and persisted urinary retention in
2.4% of 243 patients who received a PVS after a mean of 60months of follow-up. In all, 83% of the patients in this study reported high satisfac­tion and overall improvement in their quality of life [4].

Pubovaginal Sling Erosion

The incidence of PBS sling erosion and exposure mainly depends on the sling material. Sling perforation occurs 15 times more in synthetic slings than in autologous slings [3]. Only a few cases of autologous sling perforation have been reported in the literature [17]. The management of sling perforation includes the removal of the sling and simple urethral repair. In all, 44%– 100% of patients developed recurrent SUI after removing the perforated sling [2, 5]. Urethral bulking agents and PVSs can be used to treat SUI after removing the perforated sling. Higher incontinence rates are observed after secondary treatments if the perforation affects the bladder neck [3].

References

1. Ackerman AL, Blaivas J, Anger JT. Female ure­thral reconstruction. Curr Bladder Dysfunct Rep. 2010;5(4):225–32. https://doi.org/10.1007/
s11884- 010- 0071- 6.
2. Amundsen CL, Flynn BJ, Webster GD.Urethral ero­sion after synthetic and nonsynthetic pubovaginal slings: differences in management and continence outcome. J Urol. 2003;170(1):134–7.; discussion 137.
https://doi.org/10.1097/01.ju.0000064442.45724.af.
3. Blaivas JG, Sandhu J. Urethral reconstruc­tion after erosion of slings in women. Curr Opin Urol. 2004;14(6):335–8. https://doi.
org/10.1097/00042307- 200411000- 00007.
4. Brubaker L, Richter HE, Norton PA, Albo M, Zyczynski HM, Chai TC, Zimmern P, Kraus S, Sirls L, Kusek JW, Stoddard A, Tennstedt S, Gormley EA, Urinary Incontinence Treatment Network. 5-year con­tinence rates, satisfaction and adverse events of burch urethropexy and fascial sling surgery for urinary incontinence. J Urol. 2012;187(4):1324–30. https://
doi.org/10.1016/j.juro.2011.11.087.
5. Clemens JQ, DeLancey JO, Faerber GJ, Westney OL, Mcguire EJ. Urinary tract erosions after syn­thetic pubovaginal slings: diagnosis and management strategy. Urology. 2000;56(4):589–94. https://doi.
org/10.1016/s0090- 4295(00)00740- 8.
6. Conces MR, Williamson SR, Montironi R, Lopez­Beltran A, Scarpelli M, Cheng L. Urethral car­uncle: clinicopathologic features of 41 cases. Hum Pathol. 2012;43(9):1400–4. https://doi.org/10.1016/j.
humpath.2011.10.015.
114
K. N. Meilika and J. S. Sandhu
7. Dalbagni G, Donat SM, Eschwège P, Herr HW, Zelefsky MJ.Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radio­therapy for carcinoma of the female urethra. J Urol. 2001;166(5):1759–61. https://www.ncbi.nlm.nih.gov/
pubmed/11586218.
8. de Mooij Y, Burger MPM, Schilthuis MS, Buist M, van der Velden J. Partial urethral resection in the surgical treatment of vulvar cancer does not have a signicant impact on urinary continence. A conrmation of an authority-based opinion. Int J Gynecol Cancer. 2007;17(1):294–7. https://doi.
org/10.1111/j.1525- 1438.2007.00788.x.
9. Derksen JW, Visser O, de la Rivière GB, Meuleman EJ, Heldeweg EA, Lagerveld BW. Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival. World J Urol. 2013;31(1):147–53.
https://doi.org/10.1007/s00345- 012- 0882- 5.
10. Dimarco DS, Dimarco CS, Zincke H, Webb MJ, Bass SE, Slezak JM, Lightner DJ.Surgical treatment for local control of female urethral carcinoma. Urol Oncol. 2004;22(5):404–9. https://doi.org/10.1016/
S1078- 1439(03)00174- 1.
11. Elliott CS. Female urethral stricture management: the initial experience of an female pelvic medicine and reconstructive surgery-trained urologist. Female Pelvic Med Reconstr Surg. 2021;27(4):e516–20.
https://doi.org/10.1097/SPV.0000000000000969.
12. Escribano Patiño G, Husillos Alonso A, Rodriguez Fernandez E, Cancho Gil MJ, Hernandez Fernandez C. Urethral stricture in women. Arch Esp Urol. 2014;67(1):129–37. https://www.ncbi.nlm.nih.gov/
pubmed/24531681.
13. Fagan GE, Hertig AT.Carcinoma of the female ure­thra; review of the literature; report of eight cases. Obstet Gynecol. 1955;6(1):1–11. https://www.ncbi.
nlm.nih.gov/pubmed/14394542.
14. Faiena I, Koprowski C, Tunuguntla H.Female ure­thral reconstruction. J Urol. 2016;195(3):557–67.
https://doi.org/10.1016/j.juro.2015.07.124.
15. Foster J, Lemack G, Zimmern P. Skene’s gland cyst excision. Int Urogynecol J. 2016;27(5):817–20.
https://doi.org/10.1007/s00192- 015- 2872- 9.
16. Gakis G, Witjes JA, Compérat E, Cowan NC, De Santis M, Lebret T, Ribal MJ, Sherif AM, European Association, of Urology. EAU guidelines on primary urethral carcinoma. Eur Urol. 2013;64(5):823–30.
https://doi.org/10.1016/j.eururo.2013.03.044.
17. Golomb J, Groutz A, Mor Y, Leibovitch I, Ramon J.Management of urethral erosion caused by a pubo­vaginal fascial sling. Urology. 2001;57(1):159–60.
https://doi.org/10.1016/s0090- 4295(00)00887- 6.
18. Greenwell TJ, Castle C, Andrich DE, MacDonald JT, Nicol DL, Mundy AR. Repeat urethrotomy and dilation for the treatment of urethral stricture are neither clinically effective nor cost-effective. J Urol. 2004;172(1):275–7. https://doi.org/10.1097/01.
ju.0000132156.76403.8f.
19. Johnson DE, O’Connell JR. Primary carcinima of female urethra. Urology. 1983;21(1):42–5. https://doi.
org/10.1016/0090- 4295(83)90120- 6.
20. Kang M, Jeong CW, Kwak C, Kim HH, Ku JH.Survival outcomes and predictive factors for female urethral cancer: long-term experience with Korean patients. J Korean Med Sci. 2015;30(8):1143–9. https://doi.
org/10.3346/jkms.2015.30.8.1143.
21. Ko EY, Williams BF, Petrou SP. Bulking agent induced early urethral prolapse after distal ure­threctomy. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(12):1511–3. https://doi.org/10.1007/
s00192- 007- 0439- 0.
22. Kobashi KC, Vasavada S, Bloschichak A, et al. Updates to surgical treatment of female stress urinary incontinence (SUI): AUA/SUFU guideline. J Urol. 2023;209(6):1091–8.
23. Lai HH, Hurtado EA, Appell RA. Large urethral prolapse formation after calcium hydroxylapa­tite (Coaptite) injection. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(9):1315–7. https://doi.
org/10.1007/s00192- 008- 0604- 0.
24. Maher CF, O’Reilly BA, Dwyer PL, Carey MP, Cornish A, Schluter P. Pubovaginal sling ver­sus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter de­ciency: a prospective randomised controlled trial. BJOG. 2005;112(6):797–801. https://doi.
org/10.1111/j.1471- 0528.2005.00547.x.
25. Merimsky E.Case prole: retention secondary to ure­thral stricture in the female. Urology. 1985; https://
pascal- francis.inist.fr/vibad/index.php?action=getRec ordDetail&idt=8673464.
26. Morgan TO Jr, Westney OL, McGuire EJ.Pubovaginal sling: 4-YEAR outcome analysis and quality of life assessment. J Urol. 2000;163(6):1845–8. https://doi.
org/10.1016/s0022- 5347(05)67557- x.
27. Narayan P, Konety B. Surgical treatment of female urethral carcinoma. Urol Clin North Am. 1992;19(2):373–82. https://www.ncbi.nlm.nih.gov/
pubmed/1574827.
28. Niknejad K, Plzak LS 3rd, Staskin DR, Loughlin KR. Autologous and synthetic urethral slings for female incontinence. Urol Clin North Am. 2002;29(3):597–611. https://doi.org/10.1016/
s0094- 0143(02)00074- 5.
29. Niu S, Didde RD, Schuchmann JK, Zoorob D. Gartner’s duct cysts: a review of surgical man­agement and a new technique using uorescein dye. Int Urogynecol J. 2020;31(1):55–61. https://doi.
org/10.1007/s00192- 019- 04091- 9.
30. Osman NI, Mangera A, Chapple CR. A system­atic review of surgical techniques used in the treatment of female urethral stricture. Eur Urol. 2013;64(6):965–73. https://doi.org/10.1016/j.
eururo.2013.07.038.
31. Palma PCR, Riccetto CLZ, Martins MHT, Herrmann V, de Fraga R, Billis A, Netto NR Jr. Massive pro­lapse of the urethral mucosa following periurethral
10 Segmental or Total Female Urethrectomy
115
injection of calcium hydroxylapatite for stress uri­nary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):670–1. https://doi.org/10.1007/
s00192- 005- 0038- x.
32. Plotti F, Zullo MA, Palaia I, Angioli R, Panici PB. Urinary incontinence after radical vulvectomy treated with Macroplastique implantation. J Minim Invasive Gynecol. 2008;15(1):113–5. https://doi.
org/10.1016/j.jmig.2007.08.607.
33. Reid GC, DeLancey JO, Hopkins MP, Roberts JA, Morley GW. Urinary incontinence following radi­cal vulvectomy. Obstet Gynecol. 1990;75(5):852–8.
https://www.ncbi.nlm.nih.gov/pubmed/2325969.
34. Romero Pérez P, Mira Llinares A.Renal and ureteral complications of urethral stenosis. Actas Urol Esp. 1995;19(6):432–40. https://europepmc.org/article/
med/8571802.
35. Rosenblum N, Nitti VW.Female urethral reconstruc­tion. Urol Clin North Am. 2011;38(1):55–64., vi.
https://doi.org/10.1016/j.ucl.2010.12.008.
36. Shah SR, Biggs GY, Rosenblum N, Nitti VW.Surgical management of Skene’s gland abscess/ infection: a contemporary series. Int Urogynecol J. 2012;23(2):159–64. https://doi.org/10.1007/
s00192- 011- 1488- y.
37. Sherman KJ, Daling JR, McKnight B, Chu J.Hormonal factors in vulvar cancer. A case-control study. J Reprod Med. 1994;39(11):857–61. https://
www.ncbi.nlm.nih.gov/pubmed/7853273.
38. Shim JS, Oh MM, Lee JG, Bae JH. Anterior ure­threctomy for primary carcinoma of the female ure­thra mimicking a urethral caruncle. Int Neurourol J. 2013;17(4):197–9. https://doi.org/10.5213/
inj.2013.17.4.197.
39. Sui W, RoyChoudhury A, Wenske S, Decastro GJ, McKiernan JM, Anderson CB. Outcomes and prognostic factors of primary urethral cancer. Urology. 2017;100:180–6. https://doi.org/10.1016/j.
urology.2016.09.042.
40. Surabhi VR, Menias CO, George V, Siegel CL, Prasad SR. Magnetic resonance imaging of female ure­thral and periurethral disorders. Radiol Clin North Am. 2013;51(6):941–53. https://doi.org/10.1016/j.
rcl.2013.07.001.
41. Wechter ME, Wu JM, Marzano D, Haefner H. Management of Bartholin duct cysts and abscesses: a systematic review. Obstet Gynecol Surv. 2009;64(6):395–404. https://doi.org/10.1097/OGX.0
b013e31819f9c76.

Transurethral Bladder Surgery

JoshuaJ.Meeks
11

Introduction

Bladder cancer (BCa) is the ninth-most common cancer in the USA, with 82,290 new diagnoses annually, including 19,870 women [4]. The sig­nicant risk factors for BCa in women are early menopause and cigarette smoking [5, 6]. Despite a lower incidence, women are diagnosed with BCa at a more advanced stage and have a higher risk of death from BCa [7]. The causes of increased aggressiveness of BCa in women are not understood, but potential mechanisms include decreased detection of early-stage BCa or bio­logically more lethal tumor subtypes [7].
The rst symptom for most BCas is gross or microscopic hematuria evaluated by imaging and cystoscopy [2]. After identifying a bladder mass, the next step is surgical removal of the tumor. Transurethral resection of a bladder tumor (TURBT) is the most frequently performed sur­gery for BCa, with nearly all patients having at least one TURBT [8]. Among urologic proce­dures, TURBT is the third most frequent proce­dure after catheterization and cystoscopy [8]. While TURBT is a routine urologic surgery, the complication rate is 4–6%, with a 30- and 90-day mortality rate of 1.3% and 3.3%, respectively [9].
J. J. Meeks (*) Departments of Urology and Biochemistry, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA e-mail: joshua.meeks@northwestern.edu
During transurethral resection of a bladder tumor (TURBT), the surgeon uses an endoscopic resec­toscope with a cautery loop directing monopolar or bipolar energy to resect the tumor [10]. Surgery is usually performed in an outpatient setting under anesthesia [11]. The guideline-directed goal of nearly every TURBT is to resect the tumor completely and obtain a pathologic stage that includes sampling the detrusor [12, 13]. While most BCas are stage I or less, called non­muscle- invasive BCa (NMIBC), a precise patho­logic evaluation of the detrusor muscle is essential for staging. In this chapter, we discuss the most common complications of TURBT, highlight their incidence in women, and describe their rec­ognition and management.

Bladder Perforation

Background The bladder is comprised of four
layers: the urothelium (in direct contact with urine), the lamina propria, the detrusor, and the fat outside the bladder. Anatomically, the bladder is located in the space of Retzius in the retroperi­toneum, but the peritoneum covers the dome and posterior bladder. Thus, perforation of the blad­der can result in an opening to the peritoneal or retroperitoneal space, depending on the location of the perforation. The overall risk of perforation is between 0.5% and 1% [3] and is directly related to tumor size [14]. Yet, in a prospective
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2025 M. Hoffman et al. (eds.), Major Complications of Female Pelvic Surgery,
https://doi.org/10.1007/978-3-031-66772-5_11
117
118
J. J. Meeks
cohort of 36 patients in whom a cystogram was routinely performed, 21 (58%) were found to have perforations [14]. Perforation has been reported at a threefold higher rate in females in some series (female and male, 7.2% and 2.6%, respectively, p<0.001) [15]. More than 80% of perforations are extraperitoneal [16]. The bladder wall has a thickness that can vary from millime­ters to centimeters, depending on the age and gender of the patient, with most women having a thinner bladder wall.
Prevention In patients with an extremely thin
bladder wall, it can be challenging to prevent bladder perforation, and complications after TURBT are inversely associated with body mass index (BMI) [17]. Yet, there are technical and anesthetic maneuvers to decrease the risk of per­foration. For each tumor resection or “swipe” of the electrocautery loop, the surgeon should attempt to identify the location of the normal bladder wall. Commonly, perforations occur when the loop is inadvertently extended past a tumor and touches the posterior wall. Perforations encountered during resection of lateral BCa are often caused by obturator nerve reex and can be mitigated by paralysis or careful resection with a “staccato” or tap-tap technique [18]. The staccato tapping of the cutting cautery can halt a resection that is deeper than anticipated, preventing a larger perforation. We recommend this stop-and-start or staccato technique to adjust the resection depth during each transurethral resection (TUR) swipe. Anterior perforations, secondary to bladder movement during breathing, can be prevented by stabilizing the bladder with the nondominant hand or controlling breathing with intubation. The thickness of the bladder, and therefore the depth of resection, can be managed by perform­ing the resection under limited bladder lling to decrease the wall tension. During a re-resection, in which a prior tumor area is mostly composed of scar tissue, perforation can be avoided by start­ing the swipe in a normal bladder area outside of the scar. Resection experience has been associ­ated with a higher risk of complications, with
TURBT performed by residents often associated with greater frequency. Finally, the use of bipolar energy has been associated with a lower risk of perforation (0.6% and 0.3%, odds ratio (OR)
0.57) [19] but not necessarily obturator reex [20].
Recognition Visual identication of the fat layer beyond the detrusor is the rst recognition of perforation. The fat layer can be either white or yellow but has a glistening appearance. In some cases, the muscle layer can have a fat layer, which may mistook for perforation. Once a blad­der perforation is recognized, the next step is performing an intraoperative cystogram to con­rm the perforation and identify the location as either intraperitoneal or extraperitoneal. Finally, manual palpation of the abdomen and pelvis can be performed to determine if irrigation has escaped the bladder and is palpable as ascites. Once a perforation is identied, the procedure should be stopped once hemostasis is achieved to avoid further extravasation of irrigation into the abdomen. A signicant advantage of bipolar over monopolar resection is using normal saline for irrigation in bipolar cautery, which will have less risk of hyponatremia if perforation occurs. Unrecognized injuries can cause abdominal pain, urinary ascites, and increased serum creati­nine values [21].
Management The management of bladder per­foration is determined by the size of the perfora­tion and its location [21]. Extraperitoneal perforations can be managed conservatively with a Foley catheter to drain the bladder for 7–10days before repeated testing with a cysto­gram to conrm healing [22]. Intraperitoneal bladder perforations are usually treated with repair by laparotomy or laparoscopy. Due to the larger volume of irrigation uids used during a transurethral resection, removal of this uid is often necessary. If a laparotomy is not neces­sary, a drain may be placed by the surgeon or interventional radiology to remove the irrigation uid.
11 Transurethral Bladder Surgery
119
Bleeding andReoperation/ Transfusion
Background It is nearly impossible to accu-
rately measure blood loss during TURBT because of the large amount of irrigation uid used for visualization. The complication rate of bleeding is 1.1% [3]. Bleeding during TURBT occurs dur­ing resection of the vascular tumor and/or resec­tion into the bladder wall for staging. Most of the larger blood vessels in the bladder are found in the detrusor layer and may be encountered during muscle resection. During TURBT, the blood vessels are sealed with fulguration and cautery [10]. Hypothesized mechanisms of postoperative bleeding include stretching of the bladder bers from urinary retention, increased abdominal pressure from straining, or decreased clotting from anti-coagulation medications. Since TURBT is an outpatient procedure, blood counts are not measured, and, for most patients, the change in hemoglobin is not signicant. The rate of transfusion after TURBT varies between 0.6% and 2.9% depending on the size of the tumor [23]. Yet, postoperative bleeding is a signicant complication requiring hospitalization and return to the operating room to control it. Bleeding is the common cause of reoperation after TURBT, occurring in 1.5% of resections [9] with readmis­sion to the hospital in 3.7% [9].
Prevention Risk factors for postoperative bleed-
ing include use of blood thinners and antiplatelet medications and broad and deep tumor resections [24]. Because of comorbid conditions, use of blood-thinning medications cannot be prevented. After resection of the tumor, hemostasis is achieved by coagulating the resection area and surrounding epithelium. Bleeding can be decreased by technical attention to each resection site and evaluation under lower hydrostatic pres­sure by underlling the bladder. Stretching of the bladder bers can be limited by the use of a post­operative catheter. Bladder irrigation, run through a three-way catheter, can decrease the formation of clots in patients after surgery and prevent cath-
eter obstruction. Preventing post-TUR straining to avoid elevations in pelvic venous pressure is also important for preventing bleeding. Avoidance of heavy lifting or strenuous activity should be emphasized. Commonly, post-resection bleeding will occur after the patient strains to have a bowel movement. Liberal use of periprocedural laxa­tives and stool softeners can help avoid this complication.
Recognition Bleeding during TURBT can occur
at any time but can often be managed technically. Starting a resection at one edge of the tumor and then progressing to the other side is a surgical strategy to decrease bleeding from the tumor bed. Achieving hemostasis is more challenging if the specimen is resected in multiple areas. A roller­ball electrode, applied with pressure in a rolling motion over the base of the tumor, can be applied after a resection to ensure hemostasis is obtained. After the TURBT, either a voiding trial or a post­operative period of catheter observation allows for identifying any hematuria. While light pink­to blush-colored urine is normal after TURBT, identifying dark, “merlot”-colored urine and/or passing clots implies higher amounts of bleeding.
Management During surgery, every effort
should be made to decrease surgical bleeding at the resection site of the tumor. This involves mul­tiple evaluations of the tumor bed. Postoperatively, a three-way irrigating catheter can be used for continuous bladder irrigation (CBI) if bleeding is identied. This often decreases the risk of clot formation but requires 23-h hospitalization. If bleeding does not improve with CBI or continues after CBI, the patient will likely need to return to the operating room for clot evacuation and fulgu­ration of bleeding. In a patient with a perforation, if bleeding occurs, CBI is not possible and return to the operation room is necessary. Unfortunately, tranexamic acid has not decreased the risk of bleeding or complications after TUR procedures [25]. During clot evacuation, we favor gentle pressure to remove clots rather than forceful pis-
120
J. J. Meeks
ton irrigation. This decreases the risk of perfora­tion. The bleeding site is often a blood vessel in the muscle layer that requires further coagula­tion. Most patients are then observed overnight to ensure that no further bleeding occurs.

Cystitis: Infection/Urinary Tract Infection (UTI)

Background The most common cause of 30-day complications are associated with infec­tions representing almost 70% of all complica­tions after TURBT [9] occurring in 2% [3]. Infection can occur before, during, and after the procedure. Before surgery, patients may be col­onized and/or at risk of recurrent UTIs. Men are more likely to be catheter-dependent, but the rate of asymptomatic bacteriuria is greater in women. During surgery, contaminated instru­ments or infections from proximity to the peri­anal ora can be the source of bacterial infection. After surgery, using catheters, com­promised bladder emptying, and necrotic tissue can be a nidus for persistent infection. UTIs can result in delayed recovery from surgery, caus­ing the postponement of intravesical therapy. Disseminated infection from sepsis is rare after TURBT.
Prevention UTIs may be prevented by routine
preoperative urinalysis. Every hospital system has a different policy on routine preoperative urine cultures for patients with uncompromised immune systems and no prior UTIs [26]. Patients with indwelling catheters should be changed before surgery, and a urine culture should be sent within 72h before surgery. If signicant bacteria are identied, the patient can be treated before surgery with an oral antibiotic, admitted for intra­venous (IV) antibiotics, or treated preoperatively with culture-directed antibiotics. Prevention of sepsis can be managed by early intervention with antibiotics.
Recognition The identication of post- operative
UTIs can be made by discussing symptoms with the patient or routine urine culture. For patients
with a catheter for >72h, sending a urine culture from the catheter before removal is reasonable. Unfortunately, the symptoms of a UTI overlap heavily with the expected bladder urgency and dysuria after TURBT.In patients with symptoms possibly consistent with UTI, we send the urine for culture to determine whether an infection is present.
Management Culture-directed antibiotics usu-
ally decrease lower urinary tract symptoms if a UTI is detected. In patients with persistent and/or recurrent UTIs after TUR, evaluation of the blad­der by cystoscopy and measurement of post-void residual are the next steps. Cystoscopy can iden­tify necrotic scar after TURBT that can be a nidus for infection and be brushed from the bladder epithelium. The post-void residual can be mea­sured to ensure that the bladder is completely emptied to prevent recurrent infections.
Noninfective Cystitis andVoiding Discomfort
Background Irritative bladder symptoms can
affect patients’ quality of life after TURBT with a frequency of 17% [27]. These symptoms often include burning (dysuria), urgency, frequency, bladder, and penile pain. Dysuria is secondary to irritation of the bladder mucosa from extensive resection or surgical manipulation of the bladder and urethra. The bladder can be further irritated by postoperative intravesical therapy with che­motherapy, a guideline-recommended treatment for patients with newly diagnosed bladder can­cers [27]. These symptoms, often heard but chal­lenging to treat by the surgeon, signicantly impact the quality of life of patients with BCa and can delay intravesical therapy.
Prevention The cause of noninfective cystitis
and discomfort after TURBT is unknown and therefore challenging to prevent. One method to decrease symptoms can be a preoperative discus­sion with the patient about expectations and potential voiding symptoms after surgery to establish expectations.
11 Transurethral Bladder Surgery
121
Recognition Most patients will have at least
mild urinary symptoms after TURBT, and dis­cussions with physicians and members of the urology team can improve communication to help decrease symptoms.
Management Most irritative voiding symptoms
will improve with time and resolve by 3–4weeks after surgery. The most common symptom of urgency can be treated with anticholinergic or overactive bladder medications [28]. Dysuria may be improved by phenazopyridine. Anti­inammatory medications can also reduce the inammatory symptoms after surgery.

Summary

Transurethral resection of a bladder tumor is a frequently performed surgery to diagnose and manage BCa [8]. The overall complication rate ranges from 4 to 6%. Complications range from mild, irritative symptoms to bladder perforation, resulting in laparotomy. Early identication and management of these complications can improve recovery and clinical outcomes for patients with BCa.

References

1. Hollenbeck BK, Miller DC, Taub D, Dunn RL, Khuri SF, Henderson WG, etal. Risk factors for adverse out­comes after transurethral resection of bladder tumors. Cancer. 2006;106:1527–35. https://doi.org/10.1002/
cncr.21765.
2. Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician. 2009;80:717–23.
3. Gregg JR, McCormick B, Wang L, Cohen P, Sun D, Penson DF, etal. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016;23(2):8198–203.
4. Siegel RL, etal. Cancer statistics, 2023. CA Cancer J Clinic. 2023;73(1):17–48. Wiley Online Library. [cited 1 Jul 2023]. Available: https://acsjournals.
onlinelibrary.wiley.com/doi/10.3322/caac.21763.
5. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC.Association between smok­ing and risk of bladder cancer among men and women. JAMA. 2011;306:737–45. https://doi.org/10.1001/
jama.2011.1142.
6. McGrath M, Michaud DS, De Vivo I.Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol. 2006;163:236–44. https://
doi.org/10.1093/aje/kwj028.
7. Matulewicz RS, Demzik AL, DeLancey JO, Popescu O, Makarov DV, Meeks JJ. Disparities in the diag­nostic evaluation of microhematuriaand implications for the detection of urologic malignancy. Urol Oncol. 2019;37(300):e1–300.e7. https://doi.org/10.1016/j.
urolonc.2019.01.007.
8. Lee F, Patel HRH, Emberton M.The “top 10” uro­logical procedures: a study of hospital episodes sta­tistics 1998–99. BJU Int. 2002;90:1–6. https://doi.
org/10.1046/j.1464- 410x.2002.02833.x.
9. Pereira JF, Pareek G, Mueller-Leonhard C, Zhang Z, Amin A, Mega A, etal. The perioperative mor­bidity of transurethral resection of bladder tumor: implications for quality improvement. Urology. 2019;125:131–7. https://doi.org/10.1016/j.
urology.2018.10.027.
10. Herr HW.Surgical factors in the treatment of super­cial and invasive bladder cancer. Urol Clin North Am. 2005;32:157–64. https://doi.org/10.1016/j.
ucl.2005.02.003.
11. Kim LHC, Patel MI. Transurethral resection of bladder tumour (TURBT). Transl Androl Urol. 2020;9:3056–72. https://doi.org/10.21037/
tau.2019.09.38.
12. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, et al. NCCN Guidelines® insights: bladder cancer, version 2.2022. J Natl Compr Cancer Netw. 2022;20:866–78. https://doi.org/10.6004/
jnccn.2022.0041.
13. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, etal. Diagnosis and treat­ment of non-muscle invasive bladder cancer: AUA/ SUO guideline. J Urol. 2016;196:1021–9. https://doi.
org/10.1016/j.juro.2016.06.049.
14. Balbay MD, Cimentepe E, Unsal A, Bayrak O, Koç A, Akbulut Z.The actual incidence of bladder perfora­tion following transurethral bladder surgery. J Urol. 2005;174:2260–2., discussion 2262–2263. https://doi.
org/10.1097/01.ju.0000181811.61199.35.
15. Herkommer K, Hofer C, Gschwend JE, Kron M, Treiber U. Gender and body mass index as risk factors for bladder perforation during primary transurethral resection of bladder tumors. J Urol. 2012;187:1566–70. https://doi.org/10.1016/j.
juro.2011.12.114.
16. Collado A, Chéchile GE, Salvador J, Vicente J.Early complications of endoscopic treatment for supercial bladder tumors. J Urol. 2000;164:1529–32.
17. Poletajew S, Krajewski W, Gajewska D, Sondka­Migdalska J, Borowik M, Buraczyński P, et al. Prediction of the risk of surgical complications in patients undergoing monopolar transurethral resec­tion of bladder tumour—a prospective multicentre observational study. Arch Med Sci. 2019;16:863–70.
https://doi.org/10.5114/aoms.2019.88430.
122
J. J. Meeks
18. Panagoda PI, Vasdev N, Gowrie-Mohan S.Avoiding the Obturator jerk during TURBT. Curr Urol. 2018;12:1–5. https://doi.org/10.1159/000447223.
19. Sugihara T, Yasunaga H, Horiguchi H, Matsui H, Nishimatsu H, Nakagawa T, et al. Comparison of perioperative outcomes including severe bladder injury between Monopolar and bipolar transurethral resection of bladder tumors: a population based comparison. J Urol. 2014;192:1355–9. https://doi.
org/10.1016/j.juro.2014.05.100.
20. Ozer K, Horsanali MO, Gorgel SN, Ozbek E.Bladder injury secondary to obturator reex is more common with plasmakinetic transurethral resection than monopolar transurethral resection of bladder cancer. Cent European J Urol. 2015;68:284–8. https://doi.
org/10.5173/ceju.2015.565.
21. Corriere JN, Sandler CM. Management of the ruptured bladder: seven years of experience with 111 cases. J Trauma. 1986;26:830–3. https://doi.
org/10.1097/00005373- 198609000- 00009.
22. Anderson RE, Keihani S, Moses RA, Nocera AP, Selph JP, Castillejo Becerra CM, et al. Current Management of Extraperitoneal Bladder Injuries: results from the multi-institutional Genito-urinary trauma study (MiGUTS). J Urol. 2020;204:538–44.
https://doi.org/10.1097/JU.0000000000001075.
23. Matulewicz RS, Sharma V, McGuire BB, Oberlin DT, Perry KT, Nadler RB.The effect of surgical duration of transurethral resection of bladder tumors on post­operative complications: an analysis of ACS NSQIP
data. Urol Oncol. 2015;33(338):e19–338.e24. https://
doi.org/10.1016/j.urolonc.2015.05.011.
24. Konishi T, Washino S, Nakamura Y, Ohshima M, Saito K, Arai Y, et al. Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study. BMC Urol. 2017;17:118.
https://doi.org/10.1186/s12894- 017- 0309- 0.
25. Pranata FH, Kloping YP, Hidayatullah F, Rahman ZA, Yogiswara N, Rahman IA, et al. The role of tranexamic acid in reducing bleeding during transure­thral resection of the prostate: an updated systematic review and meta-analysis of randomized controlled trials. Indian J Urol. 2022;38:258–67. https://doi.
org/10.4103/iju.iju_98_22.
26. Lightner DJ, Wymer K, Sanchez J, Kavoussi L.Best practice statement on urologic procedures and antimi­crobial prophylaxis. J Urol. 2020;203:351–6. https://
doi.org/10.1097/JU.0000000000000509.
27. Filson CP, Montgomery JS, Dailey SM, Crossley HS, Lentz H, Tallman CT, et al. Complications associ­ated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. Urol Oncol. 2014;32(40):e1–8. https://doi.org/10.1016/j.
urolonc.2013.04.006.
28. Sun K, Wang D, Wu G, Ma J, Wang T, Wu J, etal. Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors. Cancer Med. 2021;10:7534–41.
https://doi.org/10.1002/cam4.4278.

Partial Cystectomy

ÓscarRodríguezFaba, AlbertoBreda, andJoanPalou
12

Introduction

Partial cystectomy (PC) is a urological surgical technique in which only a portion of the bladder is resected for benign and/or oncological condi­tions [1].
The advantages include preservation of a functional and continent urinary reservoir, and potency in men [2].
Classic indications for PC include treatment of bladder cancer (BC), specically, primary, solitary, and muscle-invasive or high-grade tumors in a region of the bladder that allows com­plete excision with adequate margins, in a patient with biopsy-proved absence of carcinoma in situ (CIS) in the remaining bladder [3].
Other indications for PC include [3]:
1. The inability to resect tumors by an endo-
scopic approach because of their size or location.
2. A need for adequate biopsy of the full thick-
ness of the bladder wall.
3. Radiation-induced ulcerations.
4. A tumor overlying a ureteral orice with the
need for ureteral reimplantation.
5. Palliation of severe local symptoms.
6. Excision of a bladder tumor in a patient who refuses urinary diversion.
7. A very-high-risk patient in whom urinary diversion is deemed inappropriate.
8. Excision of a bladder diverticulum.
9. A patient with colon cancer invading the bladder.
The reality is that the real incidence is very low, and it is used mainly only in patients with tumor in a bladder diverticulum or a partial cys­tectomy in fragile patients to avoid cystectomy.
Relative and absolute contraindications for PC include the presence of multiple tumors, carci­noma in situ (CIS), prostatic and/or trigone involvement, inability to resect with secure mar­gins, prior radiation therapy, inability to maintain an adequate bladder volume after resection, evi­dence of extravesical tumor extension, and gener­ally unt patients for surgery.
The indication of PC ranges from 7 to 10% of all the cystectomies performed according to stud­ies of the National Cancer Database [4]. Nevertheless, some specic studies have assessed that PC for BC may be overperformed, at a rate of 14% versus the commonly accepted 5–6% [5].
Ó. R. Faba · A. Breda · J. Palou (*) Urology Department, Universitat Autònoma de Barcelona, Fundació Puigvert, Barcelona, Spain e-mail: jpalou@fundacio-puigvert.es
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2025 M. Hoffman et al. (eds.), Major Complications of Female Pelvic Surgery,
https://doi.org/10.1007/978-3-031-66772-5_12
123